SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer
10 references·0 citing·43 second hop
A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer (2013)A Trial-Based Cost-Effectiveness Analysis…Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context (2012)Costs of Trastuzumab in Combi…Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China (2011)Cost-Effectiveness of Adding …Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer (2010)Economic Analysis: Randomized…An updated systematic review of Health State Utility Values for osteoporosis related conditions (2009)An updated systematic review …The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer (2008)The Potential Clinical and Ec…Health state utility scores in advanced non-small cell lung cancer (2008)Health state utility scores i…Health state utilities for non small cell lung cancer (2008)Health state utilities for no…Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) (2008)Comparative clinical and econ…Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Use of Cost-Effectiveness Ana…Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Development of WHO guidelines…Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2016)Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC (2020)Cost-Effectiveness in Health and Medicine (1996)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Bias in published cost effectiveness studies: systematic review (2006)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Bulletin of the World Health Organization (1955)Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)China's health system and its reform: a review of recent studies (2009)Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer (2013)Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma (2020)Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis (2022)Modeling Valuations for EuroQol Health States (1997)The estimation of a preference-based measure of health from the SF-36 (2002)Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC Methods Programme (2006)Systematic Searching and Selection of Health State Utility Values from the Literature (2013)A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions (2014)Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS (2017)Evaluation of Trends in the Cost of Initial Cancer Treatment (2008)Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung (2011)An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis (2019)Measurement of health state utilities for economic appraisal (1986)Quality of life and pharmacoeconomics in clinical trials (1996)Variations in population health status: results from a United Kingdom national questionnaire survey (1998)Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting (2013)Health state utilities in non–small cell lung cancer: An international study (2016)Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer (2018)EuroQol: the current state of play (1996)Quality of life and pharmacoeconomics in clinical trials (1996)Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches (2010)Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches (2010)A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer (2011)Cost of care for cancer in a health maintenance organization. (1997)Decision Modelling For Health Economic Evaluation (2006)A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice (2012)Is Individualized Medicine More Cost-Effective? A Systematic Review (2014)
this work references cited by second hop

References

  • 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
  • 2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
  • 2008Health state utilities for non small cell lung cancer407 cited
  • 2009An updated systematic review of Health State Utility Values for osteoporosis related conditions132 cited
  • 2008Health state utility scores in advanced non-small cell lung cancer116 cited
  • 2008The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer86 cited
  • 2010Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer76 cited
  • 2012Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context63 cited
  • 2011Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China61 cited
  • 2008Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)61 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work